Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Director departure
Quarterly results
Appointed director
Cardiff Oncology, Inc. (TROV) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Investor presentation
Docs: "Pancreatic Cancer and Small Cell Lung Cancer Program Updates Metastatic Pancreatic Ductal Adenocarcinoma",
"Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy Pancreatic Cancer Program"
08/09/2023 8-K Quarterly results
Docs: "CARDIFF ONCOLOGY, INC. CERTIFICATE OF ELIMINATION",
"Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Investor presentation
Docs: "Investor Contact:"
07/24/2023 8-K Quarterly results
05/04/2023 8-K Quarterly results
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Quarterly results
Docs: "Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update"
03/02/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A CAXTON CORP reports a 2.2% stake in Cardiff Oncology, Inc.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EMPLOYMENT AGREEMENT",
"Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib"
01/26/2023 SC 13G ACORN BIOVENTURES, L.P. reports a 6.4% stake in Cardiff Oncology, Inc.
01/26/2023 SC 13D/A ACORN BIOVENTURES, L.P. reports a 6.4% stake in CARDIFF ONCOLOGY, INC.
11/03/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/03/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "G2 G1 M S PLK1"
09/12/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer at the ESMO Congress 2022 Durable responses to treatment, with a median duration of response of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FOLFIRI/bevacizumab in second-line KRAS-mutated mCRC",
"Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer , Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates Next trial in RAS-mutated mCRC is a randomized Phase 2 trial to demonstrate onvansertib’s contribution to SoC and position for a possible accelerated approval opportunity&#59; topline data expected in 2H 2024",
"CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING"
09/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022"
08/04/2022 8-K Quarterly results
Docs: "Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates"
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/12/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
07/08/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/14/2022 8-K/A Quarterly results
06/09/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/26/2022 EFFECT Form EFFECT - Notice of Effectiveness:
04/15/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/14/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy